CYP2D6 Substrates, Inhibitors, and Inducers
CYP2D6 metabolizes approximately 25% of clinically used drugs (>100 medications), despite accounting for less than 2% of total hepatic cytochrome P450 enzymes 1.
Major CYP2D6 Substrates
Antidepressants
- SSRIs: Fluoxetine, paroxetine, fluvoxamine, sertraline 23
- SNRIs: Venlafaxine, desvenlafaxine, duloxetine 3
- Tricyclics: Desipramine, imipramine, nortriptyline 24
- Others: Atomoxetine 56
Antipsychotics
- Aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone, zuclopenthixol 7
- Clozapine, flupentixol, olanzapine (also metabolized by CYP2D6 but no dose adjustments recommended) 7
Cardiovascular Medications
Analgesics
- Codeine, tramadol 5
Other Notable Substrates
- Dextromethorphan, debrisoquine, bufuralol 5
Strong CYP2D6 Inhibitors
Rank order of inhibitory potency (in vitro to in vivo correlation): Paroxetine > Fluoxetine ≈ Norfluoxetine > Sertraline ≥ Fluvoxamine 4
Clinical Effects of Strong Inhibitors:
- Paroxetine: Produces approximately 3-fold increase in desipramine plasma concentrations at steady state 4
- Fluoxetine (20 mg/day): Produces approximately 4-fold elevation in peak desipramine concentrations; inhibition persists for approximately 3 weeks after discontinuation due to long half-life of active metabolite norfluoxetine 48
- Quinidine: Listed as strong inhibitor 5
The mechanism of fluoxetine's prolonged CYP2D6 inhibition is primarily competitive inhibition due to strong affinity binding and long elimination half-life of both fluoxetine and norfluoxetine, allowing unbound drug to circulate for extended periods 8.
Moderate CYP2D6 Inhibitors:
- Sertraline (50 mg/day): Produces modest approximately 30% elevation in desipramine concentrations 4
- Duloxetine 3
- Cimetidine 9
Weak CYP2D6 Inhibitors:
Other Inhibitors Identified:
- Cocaine, imipramine, thioridazine 5
CYP2D6 Inducers
CYP2D6 is largely uninducible by prototypical CYP inducers such as phenobarbital, rifampin, and dexamethasone 1. The enzyme is regulated by hepatocyte nuclear factor-4alpha rather than traditional induction mechanisms 1.
Clinical Implications by Metabolizer Phenotype
Poor Metabolizers (PMs):
- Dose reductions recommended for: Aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone, zuclopenthixol 7
- Risk: Elevated drug levels leading to increased toxicity with fluoxetine, paroxetine, and venlafaxine 2
Intermediate Metabolizers (IMs):
- Dose reductions recommended for: Pimozide and zuclopenthixol 7
Ultrarapid Metabolizers (UMs):
- Dose increase or alternative drug recommended for: Haloperidol 7
- Alternative drug or dose titration for: Risperidone 7
- Consider dose increase if no clinical effect: Zuclopenthixol 7
Important Caveats
A critical finding is that 62% of FDA-listed moderate and weak inhibitors matched their classification when evaluated against primary literature, suggesting potential discordance in some classifications 9. The FDA classifications should be interpreted with clinical judgment, particularly for cimetidine, desvenlafaxine, and fluvoxamine where modifications have been suggested 9.
Drug-drug-gene interactions (DDGIs) are particularly complex with CYP2D6 due to high prevalence of genetic variation and common use of CYP2D6 inhibiting drugs 6. When multiple CYP2D6 substrates and inhibitors are combined, consider using PBPK modeling networks or consultation with clinical pharmacology for dose optimization 6.